» Articles » PMID: 16326108

Plastic and Behavioral Abnormalities in Experimental Huntington's Disease: a Crucial Role for Cholinergic Interneurons

Overview
Journal Neurobiol Dis
Specialty Neurology
Date 2005 Dec 6
PMID 16326108
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington's disease (HD) is a fatal hereditary neurodegenerative disease causing degeneration of striatal spiny neurons, whereas cholinergic interneurons are spared. This cell-type specific pathology produces an array of abnormalities including involuntary movements, cognitive impairments, and psychiatric disorders. Although the genetic mutation responsible for HD has been identified, little is known about the early synaptic changes occurring within the striatal circuitry at the onset of clinical symptoms. We therefore studied the synaptic plasticity of spiny neurons and cholinergic interneurons in two animal models of early HD. As a pathogenetic model, we used the chronic subcutaneous infusion of the mitochondrial toxin 3-nitropropionic acid (3-NP) in rats. This treatment caused striatal damage and impaired response flexibility in the cross-maze task as well as defective extinction of conditioned fear suggesting a perseverative behavior. In these animals, we observed a loss of depotentiation in striatal spiny neurons and a lack of long-term potentiation (LTP) in cholinergic interneurons. These abnormalities of striatal synaptic plasticity were also observed in R6/2 transgenic mice, a genetic model of HD, indicating that both genetic and phenotypic models of HD show cell-type specific alterations of LTP. We also found that in control rats, as well as in wild-type (WT) mice, depotentiation of spiny neurons was blocked by either scopolamine or hemicholinium, indicating that reversal of LTP requires activation of muscarinic receptors by endogenous acetylcholine. Our findings suggest that the defective plasticity of cholinergic interneurons could be the primary event mediating abnormal functioning of striatal circuits, and the loss of behavioral flexibility typical of early HD might largely depend on cell-type specific plastic abnormalities.

Citing Articles

Exploring the role of Cdk5 on striatal synaptic plasticity in a 3-NP-induced model of early stages of Huntington's disease.

Hernandez-Echeagaray E, Miranda-Barrientos J, Nieto-Mendoza E, Torres-Cruz F Front Mol Neurosci. 2024; 17:1362365.

PMID: 39569019 PMC: 11576431. DOI: 10.3389/fnmol.2024.1362365.


Pathomechanisms of behavioral abnormalities in Huntington disease: an update.

Jellinger K J Neural Transm (Vienna). 2024; 131(9):999-1012.

PMID: 38874766 DOI: 10.1007/s00702-024-02794-y.


Striatal insights: a cellular and molecular perspective on repetitive behaviors in pathology.

Burton C, Longaretti A, Zlatanovic A, Gomes G, Tonini R Front Cell Neurosci. 2024; 18:1386715.

PMID: 38601025 PMC: 11004256. DOI: 10.3389/fncel.2024.1386715.


Neuroprotective effects of silymarin in 3-nitropropionic acid-induced neurotoxicity in male mice: improving behavioral deficits by attenuating oxidative stress and neuroinflammation.

Haddadi R, Eyvari-Brooshghalan S, Makhdoomi S, Fadaiie A, Komaki A, Daneshvar A Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(4):2447-2463.

PMID: 37847410 DOI: 10.1007/s00210-023-02776-z.


CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood-Brain Barrier and Towards Specific Cellular Targeting.

DSouza A, Nozohouri S, Bleier B, Amiji M Pharm Res. 2022; 40(1):77-105.

PMID: 36380168 DOI: 10.1007/s11095-022-03433-5.